These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12003197)

  • 1. Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
    Schellens JH; Heinrich B; Lehnert M; Gore ME; Kaye SB; Dombernowsky P; Paridaens R; van Oosterom AT; Verweij J; Loos WJ; Calvert H; Pavlidis N; Cortes-Funes H; Wanders J; Roelvink M; Sessa C; Selinger K; Wissel PS; Gamucci T; Hanauske AR
    Invest New Drugs; 2002 Feb; 20(1):83-93. PubMed ID: 12003197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
    Schellens JH; Dombernowsky P; Cassidy J; Epelbaum R; Dirix L; Cox EH; Wanders J; Calabresi F; Paridaens R; Monfardini S; Wolff J; Loos WJ; Verweij J; Pavlidis N; Hanauske AR;
    Anticancer Drugs; 2001 Aug; 12(7):583-90. PubMed ID: 11487714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
    Giles FJ; Tallman MS; Garcia-Manero G; Cortes JE; Thomas DA; Wierda WG; Verstovsek S; Hamilton M; Barrett E; Albitar M; Kantarjian HM
    Cancer; 2004 Apr; 100(7):1449-58. PubMed ID: 15042679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
    Gupta E; Mick R; Ramirez J; Wang X; Lestingi TM; Vokes EE; Ratain MJ
    J Clin Oncol; 1997 Apr; 15(4):1502-10. PubMed ID: 9193346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
    Kehrer DF; Bos AM; Verweij J; Groen HJ; Loos WJ; Sparreboom A; de Jonge MJ; Hamilton M; Cameron T; de Vries EG
    J Clin Oncol; 2002 Mar; 20(5):1222-31. PubMed ID: 11870164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
    Gerrits CJ; Creemers GJ; Schellens JH; Wissel P; Planting AS; Kunka R; Selinger K; de Boer-Dennert M; Marijnen Y; Harteveld M; Verweij J
    Br J Cancer; 1996 Mar; 73(6):744-50. PubMed ID: 8611374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
    Paz-Ares L; Kunka R; DeMaria D; Cassidy J; Alden M; Beranek P; Kaye S; Littlefield D; Reilly D; Depee S; Wissel P; Twelves C; O'Dwyer P
    Br J Cancer; 1998 Nov; 78(10):1329-36. PubMed ID: 9823974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
    Desjardins JP; Abbott EA; Emerson DL; Tomkinson BE; Leray JD; Brown EN; Hamilton M; Dihel L; Ptaszynski M; Bendele RA; Richardson FC
    Anticancer Drugs; 2001 Mar; 12(3):235-45. PubMed ID: 11290871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, pharmacokinetic and biological studies of topotecan.
    O'Dwyer PJ; LaCreta FP; Haas NB; Halbherr T; Frucht H; Goosenberg E; Yao KS
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S46-52. PubMed ID: 8070027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Irinotecan pharmacokinetics].
    Chabot GG; Robert J; Lokiec F; Canal P
    Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
    de Jonge MJ; Punt CJ; Gelderblom AH; Loos WJ; van Beurden V; Planting AS; van der Burg ME; van Maanen LW; Dallaire BK; Verweij J; Wagener DJ; Sparreboom A
    J Clin Oncol; 1999 Jul; 17(7):2219-26. PubMed ID: 10561279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
    van Warmerdam LJ; Creemers GJ; Rodenhuis S; Rosing H; de Boer-Dennert M; Schellens JH; ten Bokkel Huinink WW; Davies BE; Maes RA; Verweij J; Beijnen JH
    Cancer Chemother Pharmacol; 1996; 38(3):254-60. PubMed ID: 8646800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.
    Lee JH; Lee JM; Lim KH; Kim JK; Ahn SK; Bang YJ; Hong CI
    Ann N Y Acad Sci; 2000; 922():324-5. PubMed ID: 11193913
    [No Abstract]   [Full Text] [Related]  

  • 15. An overview of the clinical pharmacology of topotecan.
    Dennis MJ; Beijnen JH; Grochow LB; van Warmerdam LJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-12-S5-18. PubMed ID: 9122737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
    Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
    J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of camptothecin analogs in the treatment of cancer: a review.
    Kehrer DF; Soepenberg O; Loos WJ; Verweij J; Sparreboom A
    Anticancer Drugs; 2001 Feb; 12(2):89-105. PubMed ID: 11261892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
    Gerrits CJ; Schellens JH; Creemers GJ; Wissel P; Planting AS; Pritchard JF; DePee S; de Boer-Dennert M; Harteveld M; Verweij J
    Br J Cancer; 1997; 76(7):946-51. PubMed ID: 9328158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
    Eckhardt SG; Baker SD; Eckardt JR; Burke TG; Warner DL; Kuhn JG; Rodriguez G; Fields S; Thurman A; Smith L; Rothenberg ML; White L; Wissel P; Kunka R; DePee S; Littlefield D; Burris HA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Mar; 4(3):595-604. PubMed ID: 9533526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.